心脏死亡器官捐献供肝肝移植182例单中心经验总结

胡良硕; 师建华; 田敏; 沙焕臣; 张晓刚; 刘学民; 刘昌; 于良; 吕毅; 王博

doi:10.3969/j.issn.1674-7445.2017.05.009

心脏死亡器官捐献供肝肝移植182例单中心经验总结

doi: 10.3969/j.issn.1674-7445.2017.05.009

710061 西安交通大学医学院第一附属医院肝胆外科

基金项目:

国家自然科学基金面上项目 81270521

详细信息

通讯作者:
王博, Email:bobwang75@126.com

中图分类号: R617
计量
- 文章访问数: 81
- HTML全文浏览量: 24
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2017-07-31
- 网络出版日期: 2021-01-19
- 刊出日期: 2017-09-15

Experience summary of 182 patients undergoing liver transplantation from donation after cardiac death in a single center

Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

More Information

Corresponding author: Wang Bo, Email: bobwang75@126.com

摘要

摘要: 目的总结心脏死亡器官捐献（DCD）供肝肝移植的临床效果。方法回顾性分析182例DCD供肝肝移植供、受者的临床资料。根据原发病不同将182例受者分为良性组（135例）及肝细胞癌（肝癌）组（47例）。比较两组受者围手术期情况及1年、3年存活率；总结受者的临床预后及术后并发症发生情况，包括移植物早期功能障碍（EAD）、血管并发症、急性肾损伤（AKI）、肺部感染、急性排斥反应、巨细胞病毒（CMV）感染及胆道并发症。结果两组受者的无肝期、手术时间、重症监护室（ICU）停留时间比较，差异均无统计学意义（均为P < 0.05）。182例受者的1年人、移植物存活率均为93.1%，3年人、移植物存活率均为84.9%。良性组受者的1年和3年存活率分别为92.5%和88.1%，肝癌组受者的1年存活率及无病存活率分别为95%和91%，3年存活率为78%。两组受者的总体存活率比较，差异无统计学意义（P=0.879）。术后并发症包括胆道并发症26例，血管并发症14例，AKI 34例，肺部感染22例，急性排斥反应11例，EAD11例，CMV感染10例，其中放置T管者的术后胆道并发症的发生率比未放置T管者明显降低（8%比19%，P < 0.05）。结论 DCD供肝肝移植是治疗各类终末期肝病及肝癌的良好手段，术后短期疗效较好。
- 肝移植 /
- 心脏死亡器官捐献 /
- 公民逝世后器官捐献 /
- 终末期肝病 /
- 癌, 肝细胞 /
- 胆道并发症 /
- 移植物早期功能障碍 /
- 急性肾损伤 /
- 肺部感染
Abstract: Objective To summarize the clinical efficacy of liver transplantation from donation after cardiac death (DCD). Methods Clinical data of both the donors and recipients (n=182) undergoing liver transplantation from DCD were retrospectively analyzed. According to the type of primary diseases, 182 recipients were divided into the benign group (n=135) and hepatocellular carcinoma (liver cancer) group (n=47). Perioperative conditions, 1-and 3-year survival rate of the recipients were statistically compared between two groups. Clinical prognosis and the incidence of postoperative complications of the recipients were summarized. Postoperative complications mainly included early allograft dysfunction (EAD), vascular complications, acute kidney injury (AKI), pulmonary infection, acute rejection, cytomegalovirus (CMV) infection and billiary tract complication. Results No statistical significance was identified in the anhepatic phase, operation time and length of intensive care unit (ICU) stay between two groups (all P < 0.05). The 1-year survival rates of the 182 recipients and grafts were 93.1%, and 84.9% for the 3-year survival rates. In the benign group, the 1-and 3-year survival rates of the recipients were 92.5% and 88.1%. In the liver cancer group, the 1-year survival rate of the recipients was 95%, 91% for the disease-free survival rate, and 78% for the 3-year survival rate, respectively. No statistical significance was noted in the overall survival rate of the recipients between two groups (P=0.879). In terms of postoperative complications, billiary tract complications occurred in 26 patients, vascular complications in 14, AKI in 34, pulmonary infection in 22, acute rejection in 11, EAD in 11 and CMV infection in 10. The incidence of postoperative billiary tract complications in patients with T-tube insertion was significantly lower than that in their counterparts without T-tube insertion (8% vs. 19%, P < 0.05). Conclusions Liver transplantation from DCD is an efficacious treatment for end-stage liver diseases and liver cancer, which yields relatively high short-term clinical efficacy.
- Liver transplantation /
- Donation after cardiac death /
- Donation after citizen's death /
- End-stage liver disease /
- Cancer, liver cell /
- Billiary tract complication /
- Early allograft dysfunction /
- Acute kidney injury /
- Pulmonary infection

HTML全文

图 1 良性组与肝癌组受者肝移植术后的累积存活率

Figure 1. Cumulative survival rate of recipients after liver transplantation between benign group and liver cancer group

下载: 全尺寸图片幻灯片

表 1 两组供、受者一般资料的比较

Table 1. Comparison of general information of donors and recipients between two groups

指标	良性组(n=135)	肝癌组(n=47)	P值
受体特征
年龄(x±s，岁)	44±11	49±10	< 0.05
性别[n (%)]			< 0.05
女	34(25)	2(4)
男	101(75)	45(96)
BMI(x±s，kg/m2)	22.1±2.9	22.2±3.4	> 0.05
MELD评分(x±s，分)	20±9	15±6	< 0.05
Child-Pugh评分(x±s，分)	10.6±1.8	9.7±2.0	> 0.05
供者特征
年龄(x±s，岁)	41±14	41±15	> 0.05
BMI(x±s，kg/m2)	22.4±3.7	22.2±2.9	> 0.05
热缺血时间(x±s，min)	9.5±2.5	9.6±2.7	> 0.05
冷缺血时间(x±s，h)	5.0±1.6	5.4±1.8	> 0.05

下载: 导出CSV

表 2 两组受者围手术期情况的比较

Table 2. Comparison of perioperative situation of recipients between two groups(x±s)

组别	n	无肝期(min)	手术时间(h)	ICU停留时间(d)
良性组	135	52±11	6.3±1.3	7±3
肝癌组	047	54±11	6.2±1.0	7±3
P值		> 0.05	> 0.05	> 0.05

下载: 导出CSV

参考文献(17)

[1]	Dubbeld J, van Hoek B, Ringers J, et al. Biliary complications after liver transplantation from donation after cardiac death donors:an analysis of risk factors and long-term outcome from a single center[J]. Ann Surg, 2015, 261(3):e64. DOI: 10.1097/SLA.0000000000000513.
[2]	Jay C, Ladner D, Wang E, et al. A comprehensive risk assessment of mortality following donation after cardiac death liver transplant-an analysis of the national registry[J]. J Hepatol, 2011, 55(4):808-813. DOI: 10.1016/j.jhep.2011.01.040.
[3]	Doyle MB, Collins K, Vachharajani N, et al. Outcomes using grafts from donors after cardiac death[J]. J Am Coll Surg, 2015, 221(1):142-152. DOI: 10.1016/j.jamcollsurg.2015.03.053.
[4]	中华医学会器官移植分会.中国心脏死亡器官捐献工作指南(第2版)[J].中华器官移植杂志, 2011, 32(12):756-758. DOI: 10.3760/cma.j.issn.0254-1785.2011.12.014. Branch of Organ Transplantation of Chinese Medical Association. Guide of donation after cardiac death in China(2nd ed)[J]. Chin J Organ Transplant, 2011, 32(12):756-758. DOI: 10.3760/cma.j.issn.0254-1785.2011.12.014.
[5]	Lewis J, Peltier J, Nelson H, et al. Development of the University of Wisconsin donation after cardiac death evaluation tool[J]. Prog Transplant, 2003, 13(4):265-273. doi: 10.1177/152692480301300405
[6]	Liu YY, Li CP, Huai MS, et al. Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma:steroid-free immunosuppression, induction immunosuppression and standard immunosuppression[J]. PLoS One, 2015, 10(3):e0120939. DOI: 10.1371/journal.pone.0120939.
[7]	Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe:an ELTR study on evolution and outcomes[J]. J Hepatol, 2013, 58(2):287-296. DOI: 10.1016/j.jhep.2012.10.016.
[8]	Campsen J, Zimmerman M, Trotter J, et al. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States with hepatitis B immunoglobulin and nucleoside/nucleotide analogues[J]. Liver Transpl, 2013, 19(9):1020-1029. DOI: 10.1002/lt.23703.
[9]	Croome KP, Lee DD, Burns JM, et al. The use of donation after cardiac death allografts does not increase recurrence of hepatocellular carcinoma[J]. Am J Transplant, 2015, 15(10):2704-2711. DOI: 10.1111/ajt.13306.
[10]	Saab S, Waterman B, Chi AC, et al. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors:a systematic review[J]. Liver Transpl, 2010, 16(3):300-307. DOI: 10.1002/lt.21998.
[11]	Taner CB, Bulatao IG, Keaveny AP, et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus[J]. Liver Transpl, 2011, 17(6):641-649. DOI: 10.1002/lt.22258.
[12]	Tao R, Ruppert K, Cruz RJ, et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts[J]. Liver Transpl, 2010, 16(11):1288-1295. DOI: 10.1002/lt.22168.
[13]	Hernandez-Alejandro R, Croome KP, Quan D, et al. Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts[J]. Transplantation, 2011, 92(6):686-689. DOI: 10.1097/TP.0b013e31822a79d2.
[14]	Ortiz J, Feyssa EL, Parsikia A, et al. Severe hepatitis C virus recurrence is nearly universal after donation after cardiac death liver transplant[J]. Exp Clin Transplant, 2011, 9(2):105-112.
[15]	Dirchwolf M, Dodge JL, Gralla J, et al. The corrected donor age for hepatitis C virus-infected liver transplant recipients[J]. Liver Transpl, 2015, 21(8):1022-1030. DOI: 10.1002/lt.24194.
[16]	Lué A, Solanas E, Baptista P, et al. How important is donor age in liver transplantation?[J]. World J Gastroenterol, 2016, 22(21):4966-4976. DOI: 10.3748/wjg.v22.i21.4966.
[17]	Hu L, Liu X, Zhang X, et al. Child-to-adult liver transplantation with donation after cardiac death donors:three case reports[J]. Medicine (Baltimore), 2016, 95(7):e2834. DOI: 10.1097/MD.0000000000002834.